ATTR-CM & Carpal Tunnel Syndrome
Dr Yousef Razvi at British Society for Heart Failure
Transthyretin amyloid cardiomyopathy (ATTR-CM) is often missed early - patients experience a delay in diagnosis of between 2-6 years. The signs are often missed because symptoms are similar to those of other common diseases, yet early detection remains a significant unmet need, because earlier intervention improves outcomes in these patients.
Carpal tunnel syndrome can be a very early sign, manifesting in 33–49% of ATTR-CM patients several years before cardiac symptoms appear.
In this 9-minute video, Dr Yousuf Razvi (Senior Clinical Fellow, National Amyloidosis Center, Royal Free Hospital, London) presents at the British Society of Heart Failure on the long-term UK prospective multicentre study ‘Educate’ – Early diagnosis of transthyretin amyloid cardiomyopathy using carpal tunnel biopsy examination. The study sought to understand if utilising biopsies at the time of routine carpal tunnel decompression can facilitate earlier diagnosis of ATTR-CM.
Prescribing information for BEYONTTRA®▼ (acoramidis) can be found here.
Register for BayerPRO
Stay up to date on future events and webinars posted by registering to BayerPRO here.
Prescribing information for BEYONTTRA®▼ (acoramidis) can be found here.
Abbreviation:
ATTR-CM, Transthyretin Amyloid Cardiomyopathy.
PP-BEY-GB-0226 | March 2026